Renaissance Technologies LLC reduced its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 12.4% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 350,800 shares of the biotechnology company’s stock after selling 49,500 shares during the period. Renaissance Technologies LLC owned about 0.87% of Seres Therapeutics worth $3,954,000 as of its most recent filing with the SEC.
A number of other large investors also recently bought and sold shares of MCRB. Vanguard Group Inc. boosted its stake in Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Seres Therapeutics during the first quarter valued at about $613,000. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at about $447,000. Finally, State Street Corp raised its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 16,671 shares in the last quarter. 75.28% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics, Inc. (NASDAQ:MCRB) opened at 12.94 on Friday. Seres Therapeutics, Inc. has a 12 month low of $8.85 and a 12 month high of $15.09. The firm’s market capitalization is $524.23 million. The firm has a 50-day moving average of $12.77 and a 200 day moving average of $10.81.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/renaissance-technologies-llc-cuts-position-in-seres-therapeutics-inc-mcrb-updated.html.
Several brokerages recently commented on MCRB. BidaskClub downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $17.00.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
What are top analysts saying about Seres Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Seres Therapeutics Inc. and related companies.